Revisión | 14 JUN 06
Hepatotoxicidad farmacológica
Actualmente, en EE.UU., la hepatotoxicidad farmacológica es la causa principal de insuficiencia hepática aguda en los pacientes derivados para trasplante hepático.
Autor/a: Dres. Victor J. Navarro, John R. Senior N Engl J Med. 354:731-9. 16 de febrero 2006
Desarrollo
1. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002;22:145-55.
2. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002;36:451-5.
3. Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology 2005;41:1179-97.
4. Bohan TP, Helton E, McDonald I, et al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology 2001;41:1405-9.
5. Lee WM. Drug-induced acute liver failure in the United State 2005: results from the U.S. Acute Liver Failure Study Group. FDA-PhRMA-AASLD Hepatotoxicity Steering Committee meeting 28 January 2005. (Accessed January 20, 2006, at http://www. fda.gov/cder/livertox/presentations2005/ William_Lee.ppt.)
6. Temple RJ. Hepatotoxicity through the years: impact on the FDA.
7. Bénichou C. Criteria of drug-induced liver disorders: report of an international consensus meeting. J Hepatol 1990;11: 272-6.
8. FDA Working Group. CDER-PhRMAAASLD Conference 2000: clinical white paper on drug-induced hepatotoxicity, November 2000.
9. Rosalski SB, McIntyre N. Biochemical investigations in the management of liver disease. In: Bircher J, Benhamou J-P, McIntyre N, Rizetto M, Rodes J, eds. Oxford handbook of clinical hepatology. 2nd ed. Oxford, England: Oxford University Press, 1999:504.
10. Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. New York: Appleton-Century-Crofts, 1978.
11. Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005;
2. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002;36:451-5.
3. Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology 2005;41:1179-97.
4. Bohan TP, Helton E, McDonald I, et al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology 2001;41:1405-9.
5. Lee WM. Drug-induced acute liver failure in the United State 2005: results from the U.S. Acute Liver Failure Study Group. FDA-PhRMA-AASLD Hepatotoxicity Steering Committee meeting 28 January 2005. (Accessed January 20, 2006, at http://www. fda.gov/cder/livertox/presentations2005/ William_Lee.ppt.)
6. Temple RJ. Hepatotoxicity through the years: impact on the FDA.
7. Bénichou C. Criteria of drug-induced liver disorders: report of an international consensus meeting. J Hepatol 1990;11: 272-6.
8. FDA Working Group. CDER-PhRMAAASLD Conference 2000: clinical white paper on drug-induced hepatotoxicity, November 2000.
9. Rosalski SB, McIntyre N. Biochemical investigations in the management of liver disease. In: Bircher J, Benhamou J-P, McIntyre N, Rizetto M, Rodes J, eds. Oxford handbook of clinical hepatology. 2nd ed. Oxford, England: Oxford University Press, 1999:504.
10. Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. New York: Appleton-Century-Crofts, 1978.
11. Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005;
Comentarios
Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024